George Pavlov - 18 Feb 2026 Form 4 Insider Report for MapLight Therapeutics, Inc. (MPLT)

Role
Director
Signature
/s/ Kristopher L. Hanson, Attorney-in-Fact
Issuer symbol
MPLT
Transactions as of
18 Feb 2026
Net transactions value
+$441,168
Form type
4
Filing time
20 Feb 2026, 18:25:04 UTC
Previous filing
18 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pavlov George Director C/O MAPLIGHT THERAPEUTICS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY /s/ Kristopher L. Hanson, Attorney-in-Fact 20 Feb 2026 0001470798

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MPLT Voting Common Stock Purchase $186,302 +10,658 $17.48 10,658 18 Feb 2026 Direct F1
transaction MPLT Voting Common Stock Purchase $77,695 +4,422 +41% $17.57 15,080 19 Feb 2026 Direct F2
transaction MPLT Voting Common Stock Purchase $177,171 +9,920 +66% $17.86 25,000 20 Feb 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.22 to $17.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.28 to $17.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.74 to $17.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.